John T. Curnutte

2016

In 2016, John T. Curnutte earned a total compensation of $2.4M as Executive Vice President, Research and Development at Portola Pharmaceuticals, a 7% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$96,863
Option Awards$959,567
Salary$430,504
Stock Awards$818,300
Other$47,821
Total$2,353,055

Curnutte received $959.6K in option awards, accounting for 41% of the total pay in 2016.

Curnutte also received $96.9K in non-equity incentive plan, $430.5K in salary, $818.3K in stock awards and $47.8K in other compensation.

Rankings

In 2016, John T. Curnutte's compensation ranked 4,172nd out of 14,075 executives tracked by ExecPay. In other words, Curnutte earned more than 70.4% of executives.

ClassificationRankingPercentile
All
4,172
out of 14,075
70th
Division
Manufacturing
1,461
out of 5,489
73rd
Major group
Chemicals And Allied Products
441
out of 1,895
77th
Industry group
Drugs
320
out of 1,538
79th
Industry
Pharmaceutical Preparations
251
out of 1,176
79th
Source: SEC filing on April 24, 2017.

Curnutte's colleagues

We found three more compensation records of executives who worked with John T. Curnutte at Portola Pharmaceuticals in 2016.

2016

William Lis

Portola Pharmaceuticals

Chief Executive Officer

2016

Mardi Dier

Portola Pharmaceuticals

Chief Financial Officer

2016

Tao Fu

Portola Pharmaceuticals

Executive Vice President, Chief Commercial and Business Officer

News

You may also like